Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B1 | P14061 | 15/20 | 0.51 |
| ▸ | HSD17B2 | P37059 | 14/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | ESR1 | P03372 | 1/20 | 0.45 |
| ▸ | ESRRG | P62508 | 1/20 | 0.45 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.45 |
| ▸ | SLC5A2 | P31639 | 3/20 | 0.43 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.43 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.43 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.43 |
| ▸ | HPGDS | O60760 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9975499 | 0.88 | HSD17B1 (0.48) | HSD17B1HSD17B2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL23221106 | 0.84 | SLC5A2 (0.46) | HSD17B1HSD17B2CYP3A4CYP2C19SLC5A2 | |
| SCHEMBL148121 | 0.80 | MAPT (0.45) | SLC5A2ABCB11ADORA3SLC5A1SLC6A4 | |
| SCHEMBL12714458 | 0.80 | SLC5A2 (0.56) | HSD17B1HSD17B2SLC5A2ABCB11ADORA3 | |
| SCHEMBL22132986 | 0.80 | SLC5A2 (0.43) | HSD17B1HSD17B2CYP3A4CYP2C19SLC5A2 | |
| SCHEMBL156898 | 0.79 | SLC5A2 (0.41) | HSD17B1HSD17B2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL146761 | 0.78 | SLC5A2 (0.40) | HSD17B1HSD17B2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL22510538 | 0.77 | SLC5A2 (0.44) | HSD17B1HSD17B2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL8591760 | 0.77 | SLC5A2 (0.57) | HSD17B1HSD17B2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL147317 | 0.77 | SLC5A2 (0.46) | HSD17B1HSD17B2SLC5A2ABCB11ADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120258913-A1 | GLUCOPYRANOSIDE COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-10-11 | — | — | US | disclosed |
| US-8202984-B2 | Glucopyranoside compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-06-19 | — | — | US | disclosed |
| US-7943788-B2 | Including the antidiabetic, antiobesity sodium glucose transport inhibitor Canagliflozin (1-( beta -D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene) | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-05-17 | — | — | US | disclosed |
| US-20110105424-A1 | GLUCOPYRANOSIDE COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105424-A1 | GLUCOPYRANOSIDE COMPOUND | UGGT1, B3GAT3, FUT6 | HSD17B1 268/4885HSD17B2 195/4885CYP3A4 163/4885 |
| US-20120258913-A1 | GLUCOPYRANOSIDE COMPOUND | UGGT1, B3GAT3, FUT6 | HSD17B1 268/4885HSD17B2 195/4885CYP3A4 163/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.